Home › Companies › AMPHASTAR PHARMACEUTICALS INC. › 2023-2024

AMPHASTAR PHARMACEUTICALS INC. 2023-2024 Proxy Voting Records

Compiled from SEC Form N-PX filings and AMPHASTAR PHARMACEUTICALS INC.’s Form 8-K, filed 2024-06-04 (Item 5.07 on EDGAR). Page generated 02 October 2026.

10Reported items
301Asset managers
2,415Fund votes
2024-06-03Meeting date

Proxy season: 2023-2024 2024-2025 2025-2026

Explore AMPHASTAR PHARMACEUTICALS INC. in the interactive database Compare manager voting policies

Official 2023-2024 meeting results reported by AMPHASTAR PHARMACEUTICALS INC.

These tallies are AMPHASTAR PHARMACEUTICALS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2024-06-04 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

AMPHASTAR PHARMACEUTICALS INC. — official shareholder meeting results, meeting held 2024-06-03
Ballot item	For	Against	Abstain	Withheld	Broker non-votes	Outcome
Elect Director: Mary Ziping Luo	36,539,361	3,238,762	16,103	--	4,897,137	Majority: yes
Elect Director: Howard Lee	30,735,084	9,041,573	17,569	--	4,897,137	Majority: yes
Elect Director: Michael A. Zasloff	28,934,721	10,836,431	23,074	--	4,897,137	Majority: yes
Elect Director: Gayle Deflin	37,568,636	2,204,679	20,911	--	4,897,137	Majority: yes
Approval of the amendment to the 2015 Equity Incentive Plan	28,069,401	11,693,213	31,612	--	4,897,137	Majority: yes

Source: AMPHASTAR PHARMACEUTICALS INC., Form 8-K, filed with the SEC on 2024-06-04 — read the filing on EDGAR.

How asset managers voted at the AMPHASTAR PHARMACEUTICALS INC. 2023-2024 meeting

Each item below shows how the 301 asset managers that disclosed a AMPHASTAR PHARMACEUTICALS INC. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of AMPHASTAR PHARMACEUTICALS INC.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.

1. To approve, on an advisory basis, the compensation of the Company's named executive officers; and

SECTION 14A SAY-ON-PAY VOTES

Combines 6 wordings of this item as funds reported it.

94% fund support · no official result

FOR 94%

The 287 asset managers below cast 94% of the shares they voted on this item FOR (31,743,231 for, 1,903,885 against).

FOR: 31,743,231 (94.3%)AGAINST: 1,903,885 (5.7%)ABSTAIN: 4,994 (0.0%)NOT VOTED: 58 (0.0%)

Largest asset managers voting on “To approve, on an advisory basis, the compensation of the Company's named executive officers; and” at AMPHASTAR PHARMACEUTICALS INC., 2023-2024
Asset manager	For	Against	Vote
BlackRock	4,707,902	21,651	For
Federated Hermes	4,092,789	0	For
Neuberger Berman	2,766,329	0	For
Vanguard	2,731,766	0	For
State Street	2,003,378	16,909	For
American Century	0	1,273,393	Against
FULLER & THALER ASSET MANAGEMENT, INC.	1,257,939	0	For
T. Rowe Price	962,753	0	For
Dimensional	934,791	0	For
Fidelity	820,882	0	For
GEODE CAPITAL MANAGEMENT, LLC	757,666	0	For
Charles Schwab	701,442	0	For
BOONE CAPITAL MANAGEMENT LLC	575,547	0	For
Epoch Investment Partners, Inc.	573,263	0	For
Invesco	559,879	0	For
Northern Trust	487,630	1,730	For
Victory Capital	395,861	5,864	For
OBERWEIS ASSET MANAGEMENT INC/	398,300	0	For
OBERWEIS FUNDS	394,600	0	For
BESSEMER INVESTMENT MANAGEMENT LLC	283,135	0	For
OLD WESTBURY FUNDS INC	283,135	0	For
Point72	270,292	0	For
PRINCIPAL GLOBAL INVESTORS	218,664	0	For
MELLON INVESTMENTS Corp	204,198	0	For
Nuveen	188,661	0	For

Showing the 25 largest of 287 asset managers. See all 287 in the interactive database.

2. To elect four Class II directors to serve until the Company's 2027 Annual Meeting of Stockholders and until each such director's successor is elected and qualified or until such director's earlier death, resignation or removal: Gayle Deflin

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 5 wordings of this item as funds reported it.

94% Majority: yes · of votes cast

FOR 94%

FOR: 37,568,636AGAINST: 2,204,679

AMPHASTAR PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Gayle Deflin”): 37,568,636 for, 2,204,679 against, per its Form 8-K filed 2024-06-04 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 48,841,343 outstanding shares: 77% for, 5% against (81% of the company cast a for/against vote).

The 93 asset managers below cast 92% of the shares they voted on this item FOR (16,015,958 for, 1,348,166 against).

FOR 92%8%

FOR: 16,015,958 (92.2%)AGAINST: 1,348,166 (7.8%)ABSTAIN: 4,323 (0.0%)

Largest asset managers voting on “To elect four Class II directors to serve until the Company's 2027 Annual Meeting of Stockholders and until ea” at AMPHASTAR PHARMACEUTICALS INC., 2023-2024
Asset manager	For	Against	Abstain	Vote
BlackRock	3,590,722	0	0	For
Vanguard	2,618,070	0	0	For
Federated Hermes	2,046,394	0	0	For
Capitol Series Trust	1,200,192	0	0	For
Neuberger Berman	1,108,310	0	0	For
Dimensional	0	830,819	0	Against
Fidelity	794,105	0	0	For
State Street	634,430	1,578	0	For
American Century	634,419	0	0	For
T. Rowe Price	0	439,674	0	Against
OBERWEIS FUNDS	394,600	0	0	For
Charles Schwab	342,804	0	0	For
OLD WESTBURY FUNDS INC	283,135	0	0	For
Invesco	268,041	0	0	For
Victory Capital	190,615	0	0	For
TIAA	187,111	0	0	For
Janus Detroit Street Trust	134,139	0	0	For
Brighthouse	114,784	2,376	4,323	For
Equitable	104,001	0	0	For
Columbia Threadneedle	101,339	0	0	For
MoA Funds Corp	96,332	0	0	For
Jackson National	80,614	13,624	0	For
World Funds Trust	74,562	0	0	For
SEI	74,312	0	0	For
BNY Mellon	71,129	0	0	For

Showing the 25 largest of 93 asset managers. See all 93 in the interactive database.

3. To elect four Class II directors to serve until the Company's 2027 Annual Meeting of Stockholders and until each such director's successor is elected and qualified or until such director's earlier death, resignation or removal: Howard Lee

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 5 wordings of this item as funds reported it.

77% Majority: yes · of votes cast

FOR 77%AGAINST 23%

FOR: 30,735,084AGAINST: 9,041,573

AMPHASTAR PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Howard Lee”): 30,735,084 for, 9,041,573 against, per its Form 8-K filed 2024-06-04 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 48,841,343 outstanding shares: 63% for, 19% against (81% of the company cast a for/against vote).

The 93 asset managers below cast 70% of the shares they voted on this item FOR (12,077,606 for, 5,286,518 against).

FOR 70%AGAINST 30%

FOR: 12,077,606 (69.5%)AGAINST: 5,286,518 (30.4%)ABSTAIN: 4,323 (0.0%)

Largest asset managers voting on “To elect four Class II directors to serve until the Company's 2027 Annual Meeting of Stockholders and until ea” at AMPHASTAR PHARMACEUTICALS INC., 2023-2024
Asset manager	For	Against	Abstain	Vote
BlackRock	3,590,722	0	0	For
Vanguard	2,618,070	0	0	For
Federated Hermes	2,046,394	0	0	For
Capitol Series Trust	0	1,200,192	0	Against
Neuberger Berman	1,108,310	0	0	For
Dimensional	0	830,819	0	Against
Fidelity	752,003	42,102	0	For
State Street	628,625	7,383	0	For
American Century	0	634,419	0	Against
T. Rowe Price	0	439,674	0	Against
OBERWEIS FUNDS	0	394,600	0	Against
Charles Schwab	342,804	0	0	For
OLD WESTBURY FUNDS INC	0	283,135	0	Against
Invesco	268,041	0	0	For
Victory Capital	0	190,615	0	Against
TIAA	0	187,111	0	Against
Janus Detroit Street Trust	0	134,139	0	Against
Brighthouse	101,048	16,112	4,323	For
Equitable	104,001	0	0	For
Columbia Threadneedle	0	101,339	0	Against
MoA Funds Corp	0	96,332	0	Against
Jackson National	0	94,238	0	Against
World Funds Trust	74,562	0	0	For
SEI	74,312	0	0	For
BNY Mellon	0	71,129	0	Against

Showing the 25 largest of 93 asset managers. See all 93 in the interactive database.

4. To elect four Class II directors to serve until the Company's 2027 Annual Meeting of Stockholders and until each such director's successor is elected and qualified or until such director's earlier death, resignation or removal: Mary Ziping Luo

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 5 wordings of this item as funds reported it.

92% Majority: yes · of votes cast

FOR 92%8%

FOR: 36,539,361AGAINST: 3,238,762

AMPHASTAR PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Mary Ziping Luo”): 36,539,361 for, 3,238,762 against, per its Form 8-K filed 2024-06-04 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 48,841,343 outstanding shares: 75% for, 7% against (81% of the company cast a for/against vote).

The 93 asset managers below cast 91% of the shares they voted on this item FOR (15,779,001 for, 1,585,123 against).

FOR 91%9%

FOR: 15,779,001 (90.8%)AGAINST: 1,585,123 (9.1%)ABSTAIN: 4,323 (0.0%)

Largest asset managers voting on “To elect four Class II directors to serve until the Company's 2027 Annual Meeting of Stockholders and until ea” at AMPHASTAR PHARMACEUTICALS INC., 2023-2024
Asset manager	For	Against	Abstain	Vote
BlackRock	3,590,722	0	0	For
Vanguard	2,618,070	0	0	For
Federated Hermes	2,046,394	0	0	For
Capitol Series Trust	1,200,192	0	0	For
Neuberger Berman	1,108,310	0	0	For
Dimensional	0	830,819	0	Against
Fidelity	794,105	0	0	For
State Street	9,822	626,186	0	Against
American Century	634,419	0	0	For
T. Rowe Price	439,674	0	0	For
OBERWEIS FUNDS	394,600	0	0	For
Charles Schwab	342,804	0	0	For
OLD WESTBURY FUNDS INC	283,135	0	0	For
Invesco	268,041	0	0	For
Victory Capital	190,615	0	0	For
TIAA	187,111	0	0	For
Janus Detroit Street Trust	134,139	0	0	For
Brighthouse	117,160	0	4,323	For
Equitable	104,001	0	0	For
Columbia Threadneedle	101,339	0	0	For
MoA Funds Corp	96,332	0	0	For
Jackson National	80,614	13,624	0	For
World Funds Trust	74,562	0	0	For
SEI	74,312	0	0	For
BNY Mellon	71,129	0	0	For

Showing the 25 largest of 93 asset managers. See all 93 in the interactive database.

5. To elect four Class II directors to serve until the Company's 2027 Annual Meeting of Stockholders and until each such director's successor is elected and qualified or until such director's earlier death, resignation or removal: Michael A. Zasloff

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 5 wordings of this item as funds reported it.

73% Majority: yes · of votes cast

FOR 73%AGAINST 27%

FOR: 28,934,721AGAINST: 10,836,431

AMPHASTAR PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Michael A. Zasloff”): 28,934,721 for, 10,836,431 against, per its Form 8-K filed 2024-06-04 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 48,841,343 outstanding shares: 59% for, 22% against (81% of the company cast a for/against vote).

The 93 asset managers below cast 64% of the shares they voted on this item FOR (11,105,723 for, 6,258,401 against).

FOR 64%AGAINST 36%

FOR: 11,105,723 (63.9%)AGAINST: 6,258,401 (36.0%)ABSTAIN: 4,323 (0.0%)

Largest asset managers voting on “To elect four Class II directors to serve until the Company's 2027 Annual Meeting of Stockholders and until ea” at AMPHASTAR PHARMACEUTICALS INC., 2023-2024
Asset manager	For	Against	Abstain	Vote
BlackRock	3,590,722	0	0	For
Vanguard	2,618,070	0	0	For
Federated Hermes	2,046,394	0	0	For
Capitol Series Trust	0	1,200,192	0	Against
Neuberger Berman	1,108,310	0	0	For
Dimensional	0	830,819	0	Against
Fidelity	752,003	42,102	0	For
State Street	4,017	631,991	0	Against
American Century	0	634,419	0	Against
T. Rowe Price	0	439,674	0	Against
OBERWEIS FUNDS	0	394,600	0	Against
Charles Schwab	342,804	0	0	For
OLD WESTBURY FUNDS INC	0	283,135	0	Against
Invesco	0	268,041	0	Against
Victory Capital	0	190,615	0	Against
TIAA	0	187,111	0	Against
Janus Detroit Street Trust	0	134,139	0	Against
Brighthouse	101,048	16,112	4,323	For
Equitable	57,901	46,100	0	For
Columbia Threadneedle	0	101,339	0	Against
MoA Funds Corp	0	96,332	0	Against
Jackson National	0	94,238	0	Against
World Funds Trust	74,562	0	0	For
SEI	74,312	0	0	For
BNY Mellon	0	71,129	0	Against

Showing the 25 largest of 93 asset managers. See all 93 in the interactive database.

6. To approve the amendment and restatement of our 2015 Equity Incentive Plan.

COMPENSATIONMajority of the votes cast: yes

Combines 2 wordings of this item as funds reported it.

71% Majority: yes · of votes cast

FOR 71%AGAINST 29%

FOR: 28,069,401AGAINST: 11,693,213

AMPHASTAR PHARMACEUTICALS INC.’s own tally for this item (“Approval of the amendment to the 2015 Equity Incentive Plan”): 28,069,401 for, 11,693,213 against, per its Form 8-K filed 2024-06-04 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 48,841,343 outstanding shares: 57% for, 24% against (81% of the company cast a for/against vote).

The 91 asset managers below cast 69% of the shares they voted on this item FOR (11,189,376 for, 4,943,221 against).

FOR 69%AGAINST 31%

FOR: 11,189,376 (69.3%)AGAINST: 4,943,221 (30.6%)ABSTAIN: 6,769 (0.0%)

Largest asset managers voting on “To approve the amendment and restatement of our 2015 Equity Incentive Plan.” at AMPHASTAR PHARMACEUTICALS INC., 2023-2024
Asset manager	For	Against	Abstain	Vote
BlackRock	3,590,722	0	0	For
Vanguard	2,618,070	0	0	For
Federated Hermes	2,046,394	0	0	For
Neuberger Berman	1,108,310	0	0	For
Dimensional	0	830,819	0	Against
Fidelity	727,614	66,491	0	For
State Street	4,017	631,991	0	Against
American Century	0	634,419	0	Against
T. Rowe Price	0	439,674	0	Against
OBERWEIS FUNDS	0	394,600	0	Against
Charles Schwab	342,804	0	0	For
OLD WESTBURY FUNDS INC	0	283,135	0	Against
Invesco	0	268,041	0	Against
Victory Capital	0	190,615	0	Against
TIAA	187,111	0	0	For
Janus Detroit Street Trust	0	134,139	0	Against
Brighthouse	101,048	16,112	4,323	For
Equitable	57,901	46,100	0	For
Columbia Threadneedle	0	101,339	0	Against
MoA Funds Corp	0	96,332	0	Against
Jackson National	0	94,238	0	Against
World Funds Trust	0	74,562	0	Against
SEI	74,312	0	0	For
BNY Mellon	0	71,129	0	Against
QUANTITATIVE MASTER SERIES LLC	70,402	0	0	For

Showing the 25 largest of 91 asset managers. See all 91 in the interactive database.

7. To ratify the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for its fiscal year ending December 31, 2024;

AUDIT-RELATED

Combines 4 wordings of this item as funds reported it.

99.9% fund support · no official result

FOR 99.9%

The 89 asset managers below cast 99.9% of the shares they voted on this item FOR (16,134,477 for, 516 against).

FOR: 16,134,477 (100.0%)AGAINST: 516 (0.0%)ABSTAIN: 4,323 (0.0%)

Largest asset managers voting on “To ratify the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm ” at AMPHASTAR PHARMACEUTICALS INC., 2023-2024
Asset manager	For	Against	Abstain	Vote
BlackRock	3,590,722	0	0	For
Vanguard	2,618,070	0	0	For
Federated Hermes	2,046,394	0	0	For
Neuberger Berman	1,108,310	0	0	For
Dimensional	830,819	0	0	For
Fidelity	794,105	0	0	For
State Street	635,492	516	0	For
American Century	634,419	0	0	For
T. Rowe Price	439,674	0	0	For
OBERWEIS FUNDS	394,600	0	0	For
Charles Schwab	342,804	0	0	For
OLD WESTBURY FUNDS INC	283,135	0	0	For
Invesco	268,041	0	0	For
Victory Capital	190,615	0	0	For
TIAA	187,111	0	0	For
Janus Detroit Street Trust	134,139	0	0	For
Brighthouse	117,160	0	4,323	For
Equitable	104,001	0	0	For
Columbia Threadneedle	101,339	0	0	For
MoA Funds Corp	96,332	0	0	For
Jackson National	94,238	0	0	For
World Funds Trust	74,562	0	0	For
SEI	74,312	0	0	For
BNY Mellon	71,129	0	0	For
QUANTITATIVE MASTER SERIES LLC	70,402	0	0	For

Showing the 25 largest of 89 asset managers. See all 89 in the interactive database.

8. Advisory Vote to Ratify Named Executive Officers' Compensation

SECTION 14A SAY-ON-PAY VOTES

78% fund support · no official result

FOR 78%AGAINST 22%

The 9 asset managers below cast 78% of the shares they voted on this item FOR (1,250,997 for, 362,116 against).

FOR: 1,250,997 (77.6%)AGAINST: 362,116 (22.4%)

Largest asset managers voting on “Advisory Vote to Ratify Named Executive Officers' Compensation” at AMPHASTAR PHARMACEUTICALS INC., 2023-2024
Asset manager	For	Against	Vote
Capitol Series Trust	1,200,192	0	For
NORDEA INVESTMENT MANAGEMENT AB	0	333,014	Against
JPMorgan	36,674	0	For
Empower	0	28,782	Against
ADVISORY RESEARCH INC	13,329	0	For
Triasima Portfolio Management inc.	695	0	For
Desjardins Global Asset Management Inc.	0	320	Against
CORNELL UNIVERSITY	107	0	For
Trivant Custom Portfolio Group, LLC	0	0	--

9. Amend Omnibus Stock Plan

COMPENSATIONMajority of the votes cast: yes

71% Majority: yes · of votes cast

FOR 71%AGAINST 29%

FOR: 28,069,401AGAINST: 11,693,213

The 3 asset managers below cast 0% of the shares they voted on this item FOR (0 for, 1,229,081 against).

AGAINST 100%

AGAINST: 1,229,081 (100.0%)

Largest asset managers voting on “Amend Omnibus Stock Plan” at AMPHASTAR PHARMACEUTICALS INC., 2023-2024
Asset manager	Against	Vote
Capitol Series Trust	1,200,192	Against
Empower	28,782	Against
CORNELL UNIVERSITY	107	Against

10. Ratify Ernst & Young LLP as Auditors

AUDIT-RELATED

100% fund support · no official result

FOR 100%

The 3 asset managers below cast 100% of the shares they voted on this item FOR (1,229,081 for, 0 against).

FOR: 1,229,081 (100.0%)

Largest asset managers voting on “Ratify Ernst & Young LLP as Auditors” at AMPHASTAR PHARMACEUTICALS INC., 2023-2024
Asset manager	For	Vote
Capitol Series Trust	1,200,192	For
Empower	28,782	For
CORNELL UNIVERSITY	107	For

Largest AMPHASTAR PHARMACEUTICALS INC. shareholders voting in 2023-2024

Ranked by the number of AMPHASTAR PHARMACEUTICALS INC. shares each manager voted on the most widely held ballot item of the 2023-2024 meeting, shown as a share of the 48,841,343 shares outstanding at the time of that meeting.

Top AMPHASTAR PHARMACEUTICALS INC. shareholders by shares voted, 2023-2024
#	Asset manager	% of shares outstanding
1	BlackRock	9.68%
2	Federated Hermes	8.38%
3	Neuberger Berman	5.66%
4	Vanguard	5.59%
5	State Street	4.14%
6	American Century	2.61%
7	FULLER & THALER ASSET MANAGEMENT, INC.	2.58%
8	T. Rowe Price	1.97%
9	Dimensional	1.91%
10	Fidelity	1.68%

Reported AMPHASTAR PHARMACEUTICALS INC. ownership

Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).

AMPHASTAR PHARMACEUTICALS INC. beneficial owners on record for the 2023-2024 proxy season
Holder	% outstanding	Disclosure
Jack Yongfeng Zhang	27.51%	13G
Jack Y. Zhang	26.15%	DEF14A
Mary Z. Luo	26.15%	DEF14A
Applied Physics & Chemistry Laboratories, Inc.	13.98%	DEF14A
BlackRock	11.23%	13F
Vanguard Group	5.39%	13F
State Street	3.10%	13F
Dimensional Fund Advisors	2.42%	13F
Geode Capital	1.77%	13F
Renaissance Technologies	1.23%	13F

Percentages above are of 48,841,343 shares outstanding, as reported by AMPHASTAR PHARMACEUTICALS INC. on its Form 10-Q dated 2024-03-31 (see the filing on EDGAR). This is the count contemporaneous with the 2023-2024 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from AMPHASTAR PHARMACEUTICALS INC.’s 10-Q dated 2024-03-31. This page is a static snapshot rebuilt weekly on 02 October 2026; a live search always shows the current data.

At AMPHASTAR PHARMACEUTICALS INC.'s shareholder meeting held 2024-06-03, in the 2023-2024 proxy season, 301 asset managers reported how they voted in their SEC Form N-PX filings, covering 2,415 separate fund positions. Their filings are grouped here into 10 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. AMPHASTAR PHARMACEUTICALS INC.'s own Form 8-K tally for this meeting is published below, but no row in it could be matched to the most widely held item, so this page states no certified outcome for that item. On that item — To approve, on an advisory basis, the compensation of the Company's named executive officers… — the reporting funds cast 94% of the shares they voted in favour (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). That is the aggregate of those managers' own N-PX disclosures, not the company's certified result, and the funds are a subset of all shareholders.

AMPHASTAR PHARMACEUTICALS INC. proxy season coverage: 2023-2024 (this page) · 2024-2025 · 2025-2026.